Recombinant Human Hemopexin Protein, CF

R&D Systems | Catalog # 4490-HP

R&D Systems
Loading...

Key Product Details

  • R&D Systems NS0-derived Recombinant Human Hemopexin Protein (4490-HP)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

NS0

Accession Number

Applications

Enzyme Activity
Loading...

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human Hemopexin protein
Thr24-His462, with a C-terminal 6-His tag

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Thr24

Predicted Molecular Mass

50 kDa

SDS-PAGE

71 kDa, reducing conditions

Activity

Measured by its ability to bind protoporphyrin IX (PPP-IX).
Recombinant Human Hemopexin binds >6 µM PPP-IX, resulting in a 50% decrease in the fluorescence signal of rhHemopexin as measured under the described conditions.

Formulation, Preparation, and Storage

4490-HP
Formulation Supplied as a 0.2 μm filtered solution in MES and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: Hemopexin

Hemopexin (HPX) is a 60 kDa plasma glycoprotein with two four-bladed beta -propeller folds. This structural motif has been found in other proteins including collagenases and provides sites for protein-protein interactions (1-3). The liver is the major synthesizing organ. Expression in the central nervous system, in the retina, and in peripheral nerves has also been observed. Hemopexin belongs to the family of the acute-phase proteins whose synthesis is induced after an inflammatory event. Hemopexin participates in maintaining and recycling the iron pool by utilizing its high binding affinity toward heme composed of protoporphyrin IX and iron. It also functions in preventing oxidation caused by heme after hemolysis. Hydrophobic heme molecules can intercalate into lipid membranes and participate in the oxidation of lipid membrane components through the Fenton reaction resulting in lipid peroxidation. Hemopexin undergoes a conformational change upon the binding of heme. The conformational change allows hemopexin to interact with a specific receptor, forming a complex which is then internalized. In the plasma, it is likely that heme binds albumin (35-55 g/L) first because of the higher concentration of albumin in plasma than hemopexin (0.5-1.2 g/L), and is then transferred to hemopexin, which has a much higher affinity (Kd ~1 pM) toward heme. Heme concentrations in plasma increase after hemolysis, which is associated with several pathological conditions such as reperfusion injury and ischemia.

References

  1. Tolosano, E. and Altruda, F. (2002) DNA and Cell Biol. 21:297.
  2. Mauk, M. R. et al. (2007) Nature Pro. Rep. 24:523.
  3. Ascenzi, P. et al. (2005) IUMB Life. 57:749.

Alternate Names

Beta-1B-glycoprotein, HPX

Entrez Gene IDs

3263 (Human); 15458 (Mouse); 58917 (Rat)

Gene Symbol

HPX

UniProt

Additional Hemopexin Products

Product Documents for Recombinant Human Hemopexin Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Hemopexin Protein, CF

For research use only

Customer Reviews for Recombinant Human Hemopexin Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human Hemopexin Protein, CF and earn rewards!

Have you used Recombinant Human Hemopexin Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

View specific protocols for Recombinant Human Hemopexin Protein, CF (4490-HP):

Materials
  • Assay Buffer A: 0.1 M Sodium Borate, pH 9.0
  • Assay Buffer B: 5 mM NaOH in 50% (v/v) Glycerol and 50% (v/v) Methanol solution
  • Assay Buffer C: 50% Assay Buffer A, 50% Assay Buffer B
  • Recombinant Human Hemopexin (rhHemopexin) (Catalog # 4490-HP)
  • Protoporphyrin IX (PPP-IX) (Sigma, Catalog # P8293) Prepare 10 mM Stock in DMSO
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
  1. Dilute rhHemopexin to 60 µg/mL in Assay Buffer A.
  2. Dilute PPP-IX to 640 µM in Assay Buffer B.
  3. Dilute the 640 µM PPP-IX to 320 μM in Assay Buffer A.
  4. Prepare a curve of PPP-IX in Assay Buffer C. Make the following serial dilutions starting with the dilution made in the previous step: 320, 160, 80, 40, 20, 10, 5, 2.5, and 1.25 µM.
  5. Mix equal volumes of the PPP-IX curve dilutions and the 60 µg/mL rhHemopexin. Include a control containing Assay Buffer C and the 60 µg/mL rhHemopexin.
  6. Incubate mixtures at room temperature for 30 minutes.
  7. Load 100 µL of reaction mixtures and control into a plate.
  8. Read at excitation and emission wavelengths of 280 nm and 340 nm (top read), respectively in endpoint mode.
  9. Plot the curve to obtain the concentration of PPP-IX that results in 50% decrease in the fluorescence signal from the control.
Per Well:
  • rhHemopexin: 30 µg/mL (0.6 µM)
  • PPP-IX curve: 160, 80, 40, 20, 10, 5, 2.5, 1.25, and 0.625 µM

FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes
Loading...